Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver

Autor: Tessa V. van der Hoeven, Paul P.C. Poyck, Ruurdtje Hoekstra, Albert C.W.A. van Wijk, Robert A. F. M. Chamuleau, Ronald P.J. Oude Elferink, Dirk R. de Waart, Thomas M. van Gulik
Přispěvatelé: Other departments, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Tytgat Institute for Liver and Intestinal Research, Surgery, Gastroenterology and Hepatology
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Zdroj: Journal of hepatology, 48(2), 266-275. Elsevier
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2007.09.018
Popis: Background/Aims Clinical use of bioartificial livers (BAL) relies heavily on the development of human liver cell lines. The aim of this study was to assess the potential of the recently developed human fetal liver cell line cBAL111 for application in the AMC-BAL. Methods Laboratory-scale AMC-BAL bioreactors were loaded with 20 or 200 million cBAL111 cells and were cultured for 3days. Parameters for hepatocyte-specific function and general metabolism were determined daily using tests with culture medium or 100% human serum. The bioreactors were also analyzed for mRNA levels of liver-specific genes and histology. Results cBAL111 eliminated ammonia at a rate up to 49% of that in primary porcine hepatocytes (PPH), despite a low (1.1%) urea production. Transcript levels of glutamine synthetase (GS) were 570% of that in human liver, whereas genes of the urea cycle showed low expression. GS expression was confirmed immunohistochemically, and glutamine was produced by the cells. cBAL111 eliminated galactose (90.1% of PPH) and lidocaine (0.1% of PPH) and produced albumin (6% of PPH). Human serum did not increase function of cBAL111. Conclusions cBAL111 showed liver-specific functionality when cultured inside the AMC-BAL and eliminated ammonia mainly by the activity of GS, and not through the urea cycle.
Databáze: OpenAIRE
Externí odkaz: